Two companies have received approved for a generic of the 2.5 mg tablet of anticoagulant rivaroxaban, which is used to reduce ...

The FDA approved the first generics of the direct oral anticoagulant rivaroxaban, the agency announced on Tuesday.

while outside the US Xarelto generated sales of just over $1bn for Bayer. During the same period BMS enjoyed worldwide revenues of $2 billion from Eliquis, up 30% year-on-year. Boehringer only ...

Lupin's shares increased by 21.51% over the past year. However, year-to-date (YTD), the stock has decreased by 14.21%. Over ...

While Bayer’s consumer and crop science divisions continued to slide—both in the fourth quarter and in 2024 overall—the ...

Lupin is introducing rivaroxaban tablets, 2.5 mg, which is the generic of Janssen’s Xarelto.

A big dampener to Lupin’s plans would be the potential imposition of tariff on pharma products by the Trump government.

A US government agency has hit back at a plan ... J&J has said it will now need upfront payment in full for its anticoagulant Xarelto (rivaroxaban) and immunology therapy Stelara (ustekinumab ...

Global pharma major Lupin Limited (Lupin) announced that it has launched rivaroxaban tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the US FDA.

This follows the final approval from the US FDA for its abbreviated new drug application (ANDA). Shares of Lupin Ltd ended at ...

Rivaroxaban Market size is expected to reach US$ 31.9 million by 2034 from US$ 16.5 million in 2024, growing at a CAGR of 6.8%. NEW YORK, NY, UNITED STATES, February 12, 2025 /EINPresswire ...

The Food and Drug Administration (FDA) has approved the first generics of Xarelto ® (rivaroxaban) 2.5mg. Xarelto 2.5mg is used, in combination with aspirin, to: Reduce the risk of major cardiovascular ...